Will gemcitabine monotherapy be dethroned as the adjuvant chemotherapy in pancreatic adenocarcinoma?
Oncology Department, Jules Bordet Institute, Brussels, Belgium.|Oncology Department, Faculty of Medicine, Saint Joseph University, Beirut, Lebanon.
Hampig Raphael
HR
Kourie
General Surgery Department, Faculty of Medicine, Saint Joseph University, Beirut, Lebanon.
Joseph
J
Gharios
Oncology Department, Faculty of Medicine, Saint Joseph University, Beirut, Lebanon.
Joseph
J
Kattan
D000230:Adenocarcinoma / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D015415:Biomarkers; D017024:Chemotherapy, Adjuvant; D003841:Deoxycytidine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D010190:Pancreatic Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D016896:Treatment Outcome; D000093542:Gemcitabine
D000964:Antimetabolites, Antineoplastic; D015415:Biomarkers; D003841:Deoxycytidine; D000093542:Gemcitabine
capecitabine; gemcitabine; pancreatic adenocarcinoma